OpenLB
Open Library of Bioscience
Advanced Search
Clinical and vaccine immunology : CVI
Aug, 2009;16 (8): 1105-12.

Statistical approach to estimate vaccinia-specific neutralizing antibody titers using a high-throughput assay.

Richard Kennedy, V Shane Pankratz, Eric Swanson, David Watson, Hana Golding, Gregory A Poland
Author Information
  1. Richard Kennedy: Mayo Vaccine Research Group, Mayo Clinic, Guggenheim 611C, Rochester, MN 55905, USA.
PMID: 19535540 DOI: 10.1128/CVI.00109-09

Abstract

Because of the bioterrorism threat posed by agents such as variola virus, considerable time, resources, and effort have been devoted to biodefense preparation. One avenue of this research has been the development of rapid, sensitive, high-throughput assays to validate immune responses to poxviruses. Here we describe the adaptation of a beta-galactosidase reporter-based vaccinia virus neutralization assay to large-scale use in a study that included over 1,000 subjects. We also describe the statistical methods involved in analyzing the large quantity of data generated. The assay and its associated methods should prove useful tools in monitoring immune responses to next-generation smallpox vaccines, studying poxvirus immunity, and evaluating therapeutic agents such as vaccinia virus immune globulin.

References

  1. Nat Med. 2003 Sep;9(9):1131-7 [PMID: 12925846]
  2. Biologicals. 2008 Mar;36(2):105-10 [PMID: 17892944]
  3. J Infect Dis. 1997 Apr;175(4):756-63 [PMID: 9086127]
  4. Am J Epidemiol. 1986 Jun;123(6):1004-12 [PMID: 3010703]
  5. Virology. 2003 Feb 1;306(1):181-95 [PMID: 12620810]
  6. Bull World Health Organ. 1975;52(3):307-11 [PMID: 1084801]
  7. Virology. 2006 Jan 5;344(1):48-54 [PMID: 16364735]
  8. Virology. 2001 Feb 1;280(1):132-42 [PMID: 11162827]
  9. J Infect Dis. 2003 Aug 1;188(3):440-8 [PMID: 12870127]
  10. Immunol Rev. 2006 Jun;211:320-37 [PMID: 16824139]
  11. Lancet. 2005 Jan 29-Feb 4;365(9457):362-3 [PMID: 15680437]
  12. Indian J Med Res. 1977 Jun;65(6):756-9 [PMID: 203527]
  13. J Infect Dis. 2004 Feb 1;189(3):493-7 [PMID: 14745707]
  14. J Immunol. 2003 Nov 15;171(10):4969-73 [PMID: 14607890]
  15. J Infect Dis. 1990 Mar;161(3):446-8 [PMID: 2155973]
  16. Clin Infect Dis. 2008 Mar 15;46 Suppl 3:S157-67 [PMID: 18284355]
  17. J Virol. 2003 Oct;77(19):10684-8 [PMID: 12970455]
  18. Vaccine. 2007 Aug 14;25(33):6287-91 [PMID: 17597266]
  19. Microbes Infect. 2005 Apr;7(4):579-83 [PMID: 15848274]
  20. Am J Trop Med Hyg. 1972 Mar;21(2):214-8 [PMID: 5061278]
  21. J Virol. 2004 Oct;78(19):10230-7 [PMID: 15367588]
  22. Vaccine. 2005 Mar 18;23(17-18):2078-81 [PMID: 15755574]
  23. AIDS. 2007 Feb 19;21(4):521-4 [PMID: 17301573]
  24. Cell Mol Life Sci. 2006 Oct;63(19-20):2196-212 [PMID: 16964582]
  25. Nat Med. 2005 Jul;11(7):740-7 [PMID: 15951823]
  26. J Infect Dis. 2005 Feb 1;191(3):372-81 [PMID: 15633096]
  27. Prog Med Virol. 1973;16:86-108 [PMID: 4356899]
  28. Nat Med. 2006 Nov;12(11):1310-5 [PMID: 17086190]
  29. Lancet Infect Dis. 2004 Jan;4(1):15-25 [PMID: 14720564]
  30. Bull World Health Organ. 1957;16(1):63-77 [PMID: 13413647]
  31. J Virol Methods. 2008 Jun;150(1-2):14-20 [PMID: 18387679]
  32. Immunol Allergy Clin North Am. 2003 Nov;23(4):731-43 [PMID: 14753389]
  33. Infect Immun. 1978 Jan;19(1):34-9 [PMID: 624594]
  34. J Pediatr. 1978 Mar;92(3):358-62 [PMID: 416187]
  35. Virology. 2005 Sep 1;339(2):164-75 [PMID: 15993917]
  36. Viral Immunol. 1998;11(1):49-54 [PMID: 9586697]
  37. Am J Med. 2008 Dec;121(12):1058-64 [PMID: 19028201]
  38. J Virol. 2004 May;78(9):4433-43 [PMID: 15078924]
  39. JAMA. 1999 Jun 9;281(22):2127-37 [PMID: 10367824]
  40. J Gen Virol. 2008 Dec;89(Pt 12):2992-2997 [PMID: 19008384]
  41. J Gen Virol. 1980 Sep;50(1):89-100 [PMID: 7441216]
  42. J Lab Clin Med. 2003 Oct;142(4):252-7 [PMID: 14625531]
  43. Arch Pediatr Adolesc Med. 2005 Nov;159(11):1022-5 [PMID: 16275790]
  44. J Immunol. 2006 Aug 15;177(4):2552-64 [PMID: 16888017]
  45. Toxicol Appl Pharmacol. 2004 Aug 15;199(1):71-84 [PMID: 15289092]
  46. J Virol Methods. 2005 Dec;130(1-2):15-21 [PMID: 16024096]
  47. J Virol. 2008 Jul;82(14):6829-37 [PMID: 18448519]
  48. JAMA. 2003 Jun 25;289(24):3295-9 [PMID: 12824212]
  49. Clin Infect Dis. 2006 Feb 15;42(4):e16-20 [PMID: 16421781]
  50. J Clin Microbiol. 2003 Jul;41(7):3154-7 [PMID: 12843056]
  51. J Exp Med. 2004 Jun 7;199(11):1585-93 [PMID: 15184506]

Grants

  1. N01AI40065/NIAID NIH HHS
  2. AI40065/NIAID NIH HHS

MeSH Term

Adolescent
Adult
Antibodies
Data Interpretation, Statistical
Female
Humans
Male
Neutralization Tests
Smallpox Vaccine
Vaccinia virus
Young Adult

Chemicals

Antibodies
Smallpox Vaccine
Journal Article Research Support, N.I.H., Extramural
Article has an altmetric score of 3

Word Cloud

Created with Highcharts 10.0.0virusimmuneassayagentshigh-throughputresponsesdescribevacciniamethodsbioterrorismthreatposedvariolaconsiderabletimeresourceseffortdevotedbiodefensepreparationOneavenueresearchdevelopmentrapidsensitiveassaysvalidatepoxvirusesadaptationbeta-galactosidasereporter-basedneutralizationlarge-scaleusestudyincluded1000subjectsalsostatisticalinvolvedanalyzinglargequantitydatageneratedassociatedproveusefultoolsmonitoringnext-generationsmallpoxvaccinesstudyingpoxvirusimmunityevaluatingtherapeuticglobulinStatisticalapproachestimatevaccinia-specificneutralizingantibodytitersusing

Similar Articles

Cited By